Abstract
Background The World Health Organization has identified contact tracing and isolation (CTI) as a key strategy to slow transmission of SARS-CoV-2. Structured agent-based models (ABMs) provide a means to investigate the efficacy of such strategies in heterogeneous populations and to explore the impact of factors such as changes in test turnaround times (TaT).
Methods We developed a structured ABM to simulate key SARS-CoV-2 transmission and Covid-19 disease progression dynamics in populations of 10, 000 agents. We ran 10, 000 simulations of each of three scenarios: (1) No CTI with a TaT of two days, (2) CTI with a TaT of two days, and (3) CTI with a TaT of eight days. We conducted a secondary analysis in which TaT values were varied from two to 11. The primary outcome for all analyses was mean total infections.
Results CTI reduced the mean number of infections from 5, 577 to 4, 157 (a relative reduction of 25.5%) when TaT was held steady at two days. CTI with a TaT of eight days resulted in a mean of 5, 163 infections (a relative reduction of 7.4% compared to no CTI and a TaT of two days). In the secondary analysis, every additional day added to the TaT increased the total number of infections – with the greatest increase in infections between four and five days, and the smallest increase between ten and 11 days.
Conclusions In a structured ABM that simulates key dynamics of Covid-19 transmission and disease progression, CTI results in a substantial reduction in the mean number of total infections. The benefit is greater with shorter TaT times, but remained substantial even with TaTs of eight days. The results suggest that CTI may play a critical role in reducing the size of outbreaks and that TaTs should be kept as short as possible in order to maximise this benefit.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
No funding received.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
NA
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All code and data are available on GitHub.
